Postherpetic Neuralgia Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Haisco Pharma, Xenon Pharma, UCB Pharma, Teva Branded Pharma, Aestus

DelveInsight’s “Postherpetic Neuralgia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Postherpetic Neuralgia, historical and forecasted epidemiology as well as the Postherpetic Neuralgia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Postherpetic Neuralgia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Postherpetic Neuralgia Market Forecast

Some of the key facts of the Postherpetic Neuralgia Market Report: 

• The Postherpetic Neuralgia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• Sonnenreich and Dunkin (2021) estimate that one million Americans experience shingles due to herpes zoster each year. Although the rash usually goes away in 2 to 4 weeks without any serious problems, in 20% of cases nerve damage results in postherpetic neuraglia
• According to NHS UK (2021), about 1 in 5 shingles patients go on to develop postherpetic neuraglia, and those who are 50 or older are more likely to do so
• Postherpetic neuraglia is more common in women than men, according to a study by Urits et al. (2020), and the prevalence rises with age, from 1.1 per 1000 person-years in the 0-14 age group to 10.9 per 1000 person-years in the over 80 age group
• Key Postherpetic Neuralgia Companies: Lexicon Pharmaceuticals, Confo Therapeutics, Shanghai SIMR Biotech, Haisco Pharma, Xenon Pharma, Winston Laboratories, Teva Branded Pharma, Aestus Therapeutics, KAI Pharma, Takeda, Daewoong Pharma, Zalicus, Bausch Health Americas, Inc., UCB Pharma, XenoPort, Inc., and others
• Key Postherpetic Neuralgia Therapies: LX9211, CFTX-1554, SR419, LX9211, HSK16149, XPF-002, Civamide Patch, TV-45070, ATx08-001, KAI-1678, TAK-583, DWP05195, Z160, Retigabine, Levetiracetam, Gen, and others
• The Postherpetic Neuralgia epidemiology based on gender analyzed that Postherpetic Neuralgia is more prominent in females in comparison to males
• The Postherpetic Neuralgia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Postherpetic Neuralgia pipeline products will significantly revolutionize the Postherpetic Neuralgia market dynamics.

Postherpetic Neuralgia Overview

A form of neuropathic pain known as postherpetic neuralgia lasts for longer than three months after the acute phase of herpes zoster infection has subsided. In the affected dermatome (region of skin supplied by a single nerve), there is a great deal of scorching, stabbing, or shooting pain.

Get a Free sample for the Postherpetic Neuralgia Market Report 

https://www.delveinsight.com/report-store/postherpetic-neuralgia-market

Postherpetic Neuralgia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Postherpetic Neuralgia Epidemiology Segmentation:

The Postherpetic Neuralgia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Postherpetic Neuralgia
• Prevalent Cases of Postherpetic Neuralgia by severity
• Gender-specific Prevalence of Postherpetic Neuralgia
• Diagnosed Cases of Episodic and Chronic Postherpetic Neuralgia

Download the report to understand which factors are driving Postherpetic Neuralgia epidemiology trends @ Postherpetic Neuralgia Epidemiology Forecast

Postherpetic Neuralgia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Postherpetic Neuralgia market or expected to get launched during the study period. The analysis covers Postherpetic Neuralgia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Postherpetic Neuralgia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Postherpetic Neuralgia Therapies and Key Companies

• LX9211: Lexicon Pharmaceuticals
• CFTX-1554: Confo Therapeutics
• SR419: Shanghai SIMR Biotech
• LX9211: Lexicon Pharmaceuticals
• HSK16149: Haisco Pharma
• XPF-002: Xenon Pharma
• Civamide Patch: Winston Laboratories
• TV-45070: Teva Branded Pharma
• ATx08-001: Aestus Therapeutics
• KAI-1678: KAI Pharma
• TAK-583: Takeda
• DWP05195: Daewoong Pharma
• Z160: Zalicus
• Retigabine: Bausch Health Americas, Inc.
• Levetiracetam: UCB Pharma
• GEn: XenoPort, Inc.

Discover more about therapies set to grab major Postherpetic Neuralgia market share @ Postherpetic Neuralgia Treatment Market

Scope of the Postherpetic Neuralgia Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Postherpetic Neuralgia Companies: Lexicon Pharmaceuticals, Confo Therapeutics, Shanghai SIMR Biotech, Haisco Pharma, Xenon Pharma, Winston Laboratories, Teva Branded Pharma, Aestus Therapeutics, KAI Pharma, Takeda, Daewoong Pharma, Zalicus, Bausch Health Americas, Inc., UCB Pharma, XenoPort, Inc., and others
• Key Postherpetic Neuralgia Therapies: LX9211, CFTX-1554, SR419, LX9211, HSK16149, XPF-002, Civamide Patch, TV-45070, ATx08-001, KAI-1678, TAK-583, DWP05195, Z160, Retigabine, Levetiracetam, GEn, and others
• Postherpetic Neuralgia Therapeutic Assessment: Postherpetic Neuralgia current marketed and Postherpetic Neuralgia emerging therapies
• Postherpetic Neuralgia Market Dynamics: Postherpetic Neuralgia market drivers and Postherpetic Neuralgia market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Postherpetic Neuralgia Unmet Needs, KOL’s views, Analyst’s views, Postherpetic Neuralgia Market Access and Reimbursement 

To know more about Postherpetic Neuralgia companies working in the treatment market, visit @ Postherpetic Neuralgia Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Postherpetic Neuralgia Market Report Introduction

2. Executive Summary for Postherpetic Neuralgia

3. SWOT analysis of Postherpetic Neuralgia

4. Postherpetic Neuralgia Patient Share (%) Overview at a Glance

5. Postherpetic Neuralgia Market Overview at a Glance

6. Postherpetic Neuralgia Disease Background and Overview

7. Postherpetic Neuralgia Epidemiology and Patient Population

8. Country-Specific Patient Population of Postherpetic Neuralgia 

9. Postherpetic Neuralgia Current Treatment and Medical Practices

10. Postherpetic Neuralgia Unmet Needs

11. Postherpetic Neuralgia Emerging Therapies

12. Postherpetic Neuralgia Market Outlook

13. Country-Wise Postherpetic Neuralgia Market Analysis (2019–2032)

14. Postherpetic Neuralgia Market Access and Reimbursement of Therapies

15. Postherpetic Neuralgia Market Drivers

16. Postherpetic Neuralgia Market Barriers

17.  Postherpetic Neuralgia Appendix

18. Postherpetic Neuralgia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services